380
On 19 February 2007, a new orphan medicinal product was registered into the community register of orphan medicinal products under the EU orphan designation number 433. The active ingredient is HLA class I/II binding tumour associated peptides (ADF-APO-CCN-GUC-K67-MET- MMP-MUC-RGS) for treatment of renal cell carcinoma.